About BPS Bioscience
Founded in 2005, BPS Bioscience develops research tools and assay platforms that support drug discovery and translational research. The company specialises in recombinant proteins, engineered cell lines, viral tools and biochemical and cell-based assays for investigating disease mechanisms and therapeutic targets. Its technologies are widely used in immunotherapy, CAR-T and TCR therapy, cell signalling, epigenetics, DNA damage repair, metabolism and CRISPR research. By combining protein engineering, cell engineering and assay development expertise, BPS Bioscience enables researchers to perform target validation, pathway analysis and compound screening across a broad range of therapeutic areas.
The company’s portfolio includes recombinant proteins and enzymes, antibodies, reporter and knockout cell lines, lentiviral tools, luciferase assay systems and a comprehensive range of assay kits for biochemical and cellular studies. Notable product areas include immune checkpoint research tools, CAR-T development reagents, kinase and epigenetic assays, cell signalling reporter systems and inhibitor screening platforms. In addition to catalogue products, BPS Bioscience provides custom protein expression, cell line development, assay development and screening services to support preclinical drug discovery workflows.
Europa Biosite’s subsidiaries distribute for BPS Bioscience in Austria, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden, Switzerland and the United Kingdom.